31
Rejected
Greensill Capital’s approach coincided with NHS trusts’ own research into salary advance scheme providers in...
Conclusion
Greensill Capital’s approach coincided with NHS trusts’ own research into salary advance scheme providers in the context of staff financial wellbeing and employee benefits. NHS trust working papers also showed that employers considered the service could provide additional benefits, including reductions in agency bills, increased take up of additional shifts, and improved recruitment and retention. We asked NHS SBS, in its role as service provider to many NHS trusts, whether there was evidence that salary advance schemes had helped with retention or helped increase recruitment and lower agency bills. NHS SBS told us that it was too early to tell as the first pilot started in July 2020 but that the demand which started back in 2017 had continued with requests from 29 C&AG’s Report, para 22, Appendix 3; Woolard Review; 30 Q 160; C&AG’s Report, para 3.25 31 C&AG’s Report, Appendix 3, paras 4–5 The pharmacy early payment and salary advance schemes in the NHS 17 NHS trusts. NHS SBS told us that it had identified 60 NHS organisations using financial wellbeing schemes. The Committee questioned why there was a difference between what civil servants and NHS staff can access when it comes to salary advance schemes.32
Government Response Summary
The government disagrees with the need for regulation of salary advance schemes, stating it has not seen substantive evidence of consumer detriment and believes existing frameworks are sufficient. It welcomes the development of an industry code of practice and will engage with it.
Government Response
Rejected
Government Response
Rejected
HM Government
Rejected
5.1 The government disagrees with the Committee’s recommendation 5.2 Unsecured consumer credit is regulated under a legislative framework. Where consumer detriment is identified, the government is able to extend the perimeter of that framework to ensure that there is appropriate consumer protection. For example, the government is currently looking to extend regulation to cover interest-free credit agreements under 12 months and repayable in 12 or fewer payments. However, salary advance schemes generally operate entirely outside of credit regulation as the early payment of accrued wages does not usually involve the provision of credit. The government has also not seen substantive evidence of consumer detriment arising from the use of salary advance schemes. It has instead observed that these schemes can provide a useful tool to help people manage their finances, for example meeting unexpected costs or helping to manage the payment of larger one-off purchases. The government’s assessment is therefore that these schemes do not merit regulation, which would impose costs on the providers and would likely be reflected in the costs to consumers. 5.3 The government understands that firms offering salary advance schemes are developing an industry code of practice. The government welcomes this development and, alongside the FCA, is engaging with the industry as the code develops and will consider if any further interventions are needed in the event of any signs of consumer detriment.
Source
Committee
Public Accounts Committee
Inquiry
NHS supply chain finance
Report
Thirty-Fifth Report - The pharmacy early payment and salary advance schemes in the NHS
04 Feb 2022
HC 745
Addressee Bodies
HM Treasury
Timeline
Recommendation age
4.5 yrs
Report published
04 Feb 2022